Bioversys Ag receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Metrics to compare | BIOV | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBIOVPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.2x | 8.9x | −0.4x | |
PEG Ratio | 1.55 | 0.00 | 0.00 | |
Price/Book | 3.6x | 1.5x | 2.6x | |
Price / LTM Sales | 35.4x | 2.6x | 3.0x | |
Upside (Analyst Target) | 139.3% | 36.3% | 54.3% | |
Fair Value Upside | Unlock | 11.5% | 7.2% | Unlock |
BioVersys AG researches and develops antimicrobial drugs for bacterial infections. It develops BV100 that is in Phase 3 clinical trial for carbapenem-resistant Acinetobacter baumannii lung and bloodstream infections. The company is also developing Alpibectir, which is in Phase 2 clinical trial for the treatment of pulmonary and meningeal tuberculosis; BV200 to treat patients with Gram-positive S. aureus; and BV500 for non-tuberculous mycobacteria infections. It has a research and license option agreement with Shionogi & Co., Ltd. to develop ansamycin leads from the BV500 program into clinical candidates. The company was founded in 2008 and is based in Basel, Switzerland.